hydroxyphenyl)methylideneamino]-6-methyl-1,2,3,4-tetrahydro-2,4-pyrimidinedionate] (Fig. 1) , which is 1 0 3 not related to any existing classes of antifungal agents, was investigated against planktonic and biofilm-1 0 4
forming Candida spp., Cryptococcus spp., and Pneumocystis spp. resistant and four caspofungin (CAS)-resistant strains], five C. auris strains, and 18 C. neoformans strains 1 1 0 (including 12 FLC-resistant strains)was determined by the broth microdilution method (Table 1) . lower than that of FLC but higher than that one of CAS. In contrast, while certain resistant clinical 1 1 7
isolates exhibited reduced susceptibility to FLC and CAS, they were highly sensitive to the same 1 1 8
concentrations of MYC-053 as the control strains (Table 1) .
In vitro antifungal activity of MYC-053 against Pneumocystis carinii and Pneumocystis 1 2 0 murina. The responses of P. carinii and P. murina to MYC-053 were evaluated by a cytotoxicity assay 1 2 1 based on ATP-driven bioluminescence (32). The results, expressed as IC 50 after 24, 48, and 72 hours of 1 2 2 exposure to the drug, were assigned activity ranks based on the degree of reduction of ATP compared to 1 2 3 untreated controls (33,34) ( Table 2 ). The exposure of P. carinii to 1 μg/ml MYC-053 for 72 h resulted in 1 2 4 a level of ATP reduction that was slightly lower than that of pentamidine and can be considered as FLC on cryptococcal biofilms were evaluated (Table 3) . Preformed biofilms were exposed to drugs activity of MYC-053 was demonstrated in different experimental set-ups, we next evaluated the possible 1 5 0 cytotoxicity of this molecule in two eukaryotic cell lines. L2 and A549 cells were treated with increasing 1 5 1 concentrations of MYC-053 (0.1-100 μg/ml) for up to 72 h. The cytotoxicity was evaluated using an ATP 1 5 2 release assay, as described in the Materials and methods with three independent repeats at each time point which partially restores the function of the immune system, opportunistic infections caused by these fungi 1 7 2 continue to contribute to the mortality of the immunocompromised hosts (44,45). In the current study, we described a novel antifungal drug candidate, MYC-053, which exhibited 1 7 4 a high level of antimicrobial activity against C. glabrata, C. auris, C. neoformans, and Pneumocistis spp. strains. These data correspond well with the notion that MYC-053 is a representative of a novel chemical 1 7 8 class of antifungal agents; it is not relevant to the existing antifungal agents whose use is frequently characterized by cross-resistance (46). Notably, MYC-053 was effective against C. auris that is often resistant to other antifungal agents of this class, including voriconazole (48, 49) . Therefore, we propose 1 9 0 that MYC-053 might be effective against other azole-resistant strains of C. neoformans.
This investigation also revealed that MYC-053 was effective against Pneumocystis spp., other 1 9 2
yeast-like pathogens that are challenging to treat in neutropenic patients. The anti-pneumocystis activity Pneumocystis constitutes a highly sensitive assay enabling the reduction of the number of tested first new synthetic compound that can be potentially used against Pneumocistis spp., Candida spp., and 2 0 0
Cryptococcus spp..
0 1
To determine whether MYC-053 was active against preformed yeast biofilms, its MBEC values isolates.
2 0 9
Importantly, the potent antifungal activity of MYC-053 was not associated with any cytotoxicity 2 1 0 and hemolytic activity, as evaluated in a 72-h assay, suggesting a high therapeutic index. Therefore, with low toxicity and high anti-biofilm activity render the data promising. These findings suggest that 2 1 6
MYC-053 may be used to treat of fungal infections that involve biofilm formation. Taken together, the results of the current study on the efficacy of MYC-053 against certain yeasts further into an antifungal drug candidate; however, it requires more in vivo research. The test substance and antimicrobials. MYC-053 was synthesized by TGV-inhalonix Inc. Fungal strains. Forty-four fungal species were used in this study. C. glabrata CG1, C. glabrata
glabrata CG8, C. glabrata CG9, C. glabrata CG10, C. auris CAU1, C. auris CAU2, C. auris CAU3, C. performed in three wells. The medium was aspirated from the wells, the adherent cells were lysed with 2 9 8 0.1 M NaOH, and ATP content was assayed in a portion of the lysate using the luciferin-luciferase assay, Human erythrocytes from a healthy adult donor were used, as described previously (60,61,62), with a few Following 6 h of incubation at 36 O C, samples were centrifuged and the supernatants were transferred to a parametric paired Wilcoxon signed-rank test was employed to analyze the pre-and post-challenge 3 1 5 9 differences, and P < 0.05 was considered significant. All assays were conduced in triplicate, and were 3 1 6 repeated in three independent experiments. This work utilized NIAID's suite of preclinical services for in vitro assessment (Contract No. Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest: None declared. Ethical approval: Not required. Institute, Wayne, PA. Reviews 19:435-447. Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to Antifungal Effects against Cryptococcus neoformans. Frontiers in Microbiology 8. Silver Nanoparticles on Haemolysis, Platelet Function and Coagulation. Nanobiomedicine 1:4. 
